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Abstract. Among the different processes occurring during
the evolution of liver disease, fibrosis has a predominant role.
Liver fibrosis mechanisms are fairly constant irrespective of
the underlying etiology. Cirrhosis is the end-stage of this
reaction. Metabolic profiles, which are affected by many
physiological and pathological processes, may provide
further insight into the metabolic consequences of this severe
liver disease. The aim of this study was to demonstrate the
applicability of 1H high resolution magic angle spinning
(HR-MAS) NMR spectroscopy in the biochemical profile
determination of human liver needle biopsy samples for the
characterization of metabolic alterations related to the severity
of liver disease. We recorded and analyzed HR-MAS spectra
of 68 liver tissue samples obtained by needle biopsy from
patients with chronic liver disease. Multivariate analysis was
applied to these data to obtain discrimination patterns and to
reveal relevant metabolites. The metabolic characterization
of liver tissue from needle biopsies by HR-MAS NMR
spectroscopy provided differential patterns for cirrhotic and
non-cirrhotic chronic liver disease tissue. Metabolites closely
related to the liver metabolism such as some fatty acids,
glucose and amino acids show differences between the two
groups. Phospholipid precursors, which have been previously
correlated with hepatic lesions also show differences.
Furthermore, the correlation between histologically assessed
liver disease stages and the levels of the most discriminative
metabolites show that liver dysfunction is present at the
initial stages of chronic hepatic lesions. Overall, this work
suggests that the additional information obtained by NMR
metabolomics applied to needle biopsies of human liver may
be useful for assessing metabolic alterations and liver
dysfunction in chronic liver disease.
Introduction
The liver is among the most metabolically diverse organs of
the body and is involved in many critical metabolic processes
(1). One of its major roles is storing endogenous fuels of the
body. In addition, the liver acts as a major distribution center
for exogenous energy supplies. The liver may be affected by
many pathological aggressions. Liver dysfunction results in a
variety of clinical signs and symptoms. However, some of
these pathologies pose a diagnostic challenge as many
different diseases show similar clinical signs (2-4). Moreover,
liver biopsy assessment involves some degree of complication
because of the proliferation of different grading and staging
schemes (5-7). Metabolic alterations produced by liver
disease may help clinicians better characterize the disease.
Among the different processes occurring during the evolution
of liver disease, fibrosis takes a predominant role. Liver
fibrosis is characterized by the replacement of liver tissue
by fibrous scar tissue as well as regenerative nodules,
leading to progressive loss of liver function and to altered
liver metabolism (8-11). Liver fibrosis induction mechanisms
are fairly constant irrespectively of the underlying etiology
(12-16). Cirrhosis is the end-stage of this reaction and it
represents a major change in the tissue. Most of the
conventional approaches for the assessment of liver disease
rely on few biomarkers, which represent particular disease
states and often are not sufficient for providing global
biochemical characterization and definitive diagnosis (17-20).
Global metabolic profiles, which are affected by many
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physiological and pathological processes, may more accurately
reflect the presence of a particular disease state. Recent
studies of NMR lipid profiling in chronic hepatitis C show
the potential of this approach (21-24). The high metabolic
activity of the liver makes the hepatic disease a perfect
candidate for metabolic profiling. 
High resolution magic angle spinning (HR-MAS) NMR
spectroscopy is a powerful technique for the investigation of
metabolites within different intact tissues (25-31). The
precise determination of the biochemical and metabolic
profiles in intact tissue promises to extend the possibilities of
NMR as a medical diagnostic tool. For non-solid or highly
viscous liquids, HR-MAS NMR spectroscopy allows the
reduction of most of the line broadening associated with
restricted molecular motion, chemical shift anisotropy,
dipolar couplings and field heterogeneity, by high-rate
spinning of the sample at the magic angle θ=54.7˚ (32). The
potential of HR-MAS applications to the study of biological
tissues has been widely demonstrated in the investigation of
different cellular alterations (30,33). In addition, HR-MAS
NMR spectroscopy of intact tissues (ex vivo) provides further
advantages over traditional high resolution liquid NMR of
tissue extracts (in vitro) (27,34). High resolution NMR of
extracts from excised tissues requires large amounts of
sample (35). Likewise, the extraction process via protein
precipitation methods disables the direct observation of small
cellular proteins and membrane semi-mobile lipids. Moreover,
extraction methods usually discriminate metabolites on the
basis of their solubility in particular solvents. Although it has
some minor limitations associated mainly to the spinning of
the sample (spinning side-bands, spinning degradation effects
and spinning temperature gradients among others), HR-MAS
NMR is a non-destructive technique, which requires minimal
sample preparation, and allows the observation of most of the
tissue metabolites and dynamic interactions in an extremely
reduced sample quantity. This technology can supplement
histopathological examination and improve liver disease
diagnostics (21,28,36, 37). The similarities between ‘ex vivo’
and ‘in vivo’ spectra found in studies of different tumours
allow better interpretation of in vivo MR spectra and increase
the clinical potential of the method (38). HR-MAS spectra
generate metabolic profiles that contain information on the
physiological and pathological status. This approach can be
used to define the metabolomic phenotype of a tissue.
Previous studies have shown the potential of HR-MAS NMR
spectroscopy as a tool for liver disease characterization
(21,28,36). Furthermore, studies in human liver tissue
suggested the applicability of the technique in the assessment
of liver transplant viability (36).
The aim of this study was to demonstrate the applicability
of 1H HR-MAS NMR spectroscopy in the biochemical
profile determination of human liver needle biopsy samples
for the assessment of the chronic liver disease stage.
Patients and methods
Patients and tissue collection procedure. Sixty-eight samples
of liver tissue were obtained from 68 chronic liver disease
patients at the Service of Hepatology of the Hospital Clinico
Universitario of Valencia. The biopsy tissue was collected by
an anatomopathologist for routine histological analysis and
the informed consent was obtained from all patients. The
study was approved by the local Ethics Committee. The
remainder tissue was immediately put in cryogenic vials and
snap-frozen in liquid nitrogen. All samples used for
histopathological examination were fixed in formalin and
paraffin embedded by a pathologist. Routine methods were
employed for histopathological studies. All snap-frozen
samples for HR-MAS were at -80˚C until further analysis.
Liver tissue analyzed included 11 cirrhotic and 57 non-
cirrhotic samples obtained from 43 male and 25 female
patients, 32-76 years of age. Histopathological grade and
stage was assessed according to the Batts-Ludwig
classification (39). Table I gives a summary of the clinical
characterization of the patients and the biopsy samples.
Sample preparation. Liver tissue obtained for HR-MAS
measurements was stored at -80˚C until use. Due to the small
size of the samples (approximately 1-12 mg), all the
materials that were to be in contact with the tissue were
cooled to at least 4˚C to reduce tissue degradation during
the sample preparation process. Frozen samples were
placed in a cryovial and in liquid N2 until insertion in a 4-mm
outer diameter ZrO2 rotor. The whole operation took no longer
than 2 min. The pre-cooled rotor was filled with 4˚C cooled
D2O after sample insertion. Spherical inserts were used in all
the cases, limiting the rotor inner volume to 12 μl. HR-MAS
using spherical small volume inserts provides improved
resolution and line shapes compared to cylindrical inserts
(40). D2O exceeding the 12 μl volume was removed before
rotor sealing. Due to the small amount of tissue and the
possible degradation during the sample weighting process,
tissue samples were weighted only after HR-MAS
measurements.
1H HR-MAS NMR spectroscopy of intact human liver tissue.
All spectra were recorded in a Bruker Avance DRX 500
spectrometer (Valencia, Spain) operating at a 1H frequency of
500.13 MHz. The instrument was equipped with a 4 mm
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Table I. Summary of patient and sample information for this
study.
–––––––––––––––––––––––––––––––––––––––––––––––––
Chronic hepatitis Cirrhosis
–––––––––––––––––––– –––––––
Disease stage 1 2 3 4
–––––––––––––––––––––––––––––––––––––––––––––––––
Etiology
Virus C 12 20 14 6
Alcohol - 1 1 1
Virus C + Alcohol - - - 1
Cryptogenic - - - 2
Autoimmune 2 1 2 1
Virus B 2 2 - -
Age range (years) 36-60 35-66 32-68 38-76
Gender (M/F) 9/7 18/6 10/7 6/5
–––––––––––––––––––––––––––––––––––––––––––––––––
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triple resonance 1H/31P/13C HR-MAS probe. For all
experiments, samples were spun at 4000 Hz to keep the
rotation sidebands out of the acquisition window. Field
homogeneity, required for adequate resonances, line-shape
and spectral resolution, was achieved by extensive coil
shimming using the 1D water pre-saturation experiments in
the interactive mode as a control. When detected, the lactate
doublet at 1.33 ppm was used for field homogeneity
shimming, as described elsewhere (41). Sample temperature,
as calibrated using MeOH standards (38), was kept at 4˚C,
using the cooling of the inlet gas pressures responsible for
the sample spinning. The number of transients varied from
400 to 2048 depending on the tissue sample amount. Water
pre-saturation was used during the last sec of the recycling
delay in all experiments for solvent signal suppression.
Experiments acquired for all samples always included 1D
pre-saturation 1H spectra and T2 edited 1D Carr-Purcell-
Meiboom-Gill (CPMG) 1H spectra (echo time of 400 msec)
in order to minimize the contribution of macromolecules to the
profile. However, CPMG spectra did not provide enough
signal-to-noise ratios for subsequent analysis (data not shown).
2D experiments were acquired on selected samples for
assignment purposes (Fig. 2). Recycling delays were 1.5 sec
for all experiments. Chemical shift referencing was performed
relative to a cluster of fatty acid signals, which was detected
in all experiments.
Spectral analysis. All 68 spectra were processed using
TopSpin 1.5 (Bruker BioSpin GmbH, Rheinstetten, Germany)
and transferred to MATLAB (MathWorks Inc., 2006) using
in-house scripts for data analysis. The chemical shift region
including resonances between 2.00 and 4.40 ppm (the
aliphatic region) was investigated. The aromatic region did
not provide enough signal-to-noise for the subsequent
analysis. The spectra were normalized to the aliphatic
spectral area between 2.00 and 4.40 ppm containing most
intracellular metabolite signals for avoidance of major fatty
acid signal and to eliminate differences in relative fat
content. The spectra were binned into 0.01 ppm buckets and
statistical analysis was performed using in-house MATLAB
scripts and the PLS_Toolbox statistical multivariate analysis
library. A high variability among the size, weight and fat
content of the samples made it necessary to use variance
stabilization procedures. The bucketed data were then
analyzed by the Partial Least Squares Discriminant Analysis
(PLS-DA) for detecting discriminating patterns and
metabolites. The PLS-DA model was validated by the leave-
one-out method. The averaged loading plots of the
corresponding PLS-DA latent variables were used to detect
the most relevant metabolites. Signals belonging to these
selected metabolites were integrated and relative quantities
were obtained using semi-automated in-house MATLAB
peak-fitting routines over the normalized spectra. A power
calculation by the Mann-Whitney U test at the 5% significance
(·=0.05) was used for the determination of the statistical
significance of the differences between corresponding integrals
in chronic hepatitis and cirrhotic samples. Differences with
respect to the etiology were also explored in a similar
fashion. Correlation with liver disease stage was explored by
Pearson's linear correlation analysis.
Results
Spectroscopic data. Representative 1H NMR spectra of
cirrhotic and non cirrhotic chronic liver disease tissue are
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  27:  111-117,  2011 113
Figure 1. Typical spectra from a 1H HR-MAS 1D pre-saturation single-pulse
experiment for non cirrhotic (bottom) and cirrhotic (top) chronic liver
disease tissue with most relevant resonances labeled. Lip1, lipid CH3; Lip2,
lipid (CH2)n; Lip3, lipid CH2CH2CO; Lip4, lipid CH2CH=CH; Lip5, lipid
CH2CO; Lip6, CH=CHCH2-CH=CH; CCC, choline-containing compounds;
TMAO, trimethylamine-N-oxide; Bet, betaine; Ala, alanine; Glu, glutamate;
Gln, glutamine.
Figure 2. Aliphatic region of 2D 1H,1H TOCSY HR-MAS spectrum with
50 msec of mixing time for 7.5 mg of human liver tissue showing the
assignment of the most significant metabolites.
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shown in Fig. 1. The use of highly symmetric spherical
cavity inserts provided high spectral resolution and sensitivity.
All NMR spectra were dominated by broad resonances
arising from fatty acid mobile chains. Metabolite spin
systems and resonances were identified by using literature
data (28,36) and were confirmed by additional 2D homo- and
multi-nuclear experiments collected in selected samples.
The 1D single-pulse pre-saturation experiment provides
complete and unambiguous identification of the metabolic
pattern characterizing the examined tissues. Collagen,
which is a typical molecule present in fibrotic tissue, cannot
be observed by conventional NMR techniques due to its
size and restricted mobility. The high variability found in
terms of the sample size, weight and fat content resulted in
very different spectral profiles across the whole data set of
samples. In the liver, large molecules are thoroughly present
(cholesterol in lipoproteins, lipids, fatty acids, etc) and,
although not observable as sharp NMR signals, they may
partially distort the spectral baseline. The broad signals
belonging to the mobile parts of fatty acids and lipids
extensively overlapped with the sharp signals from the
lower molecular weight metabolites. In those samples with a
lower relative fat content, the decreased overlapping allowed
the detection of prominent signals from water-soluble
metabolites, such as lactate, glucose, creatine, taurine,
phosphoethanolamine, glycerophosphocholine, phospho-
choline, choline and most of the amino acids in the aliphatic
region (Fig. 1).
Multivariate analysis. HR-MAS spectra from cirrhotic and
non-cirrhotic chronic liver disease tissue samples show great
similarity probably because they are dominated by broad
fatty acid signals (Fig. 1). To establish a global overview of
the characteristics of the different types of liver tissue studied
here, multivariate data analysis was applied to the HR-MAS
data. PLS-DA analysis, which is focused on the discrimination
of different groups of samples, provided partial separation
between cirrhotic and non-cirrhotic samples (Fig. 3A). The
Latent Variable 1 (Fig. 3B) showed that the major metabolic
differences correspond to the levels of some unsaturated
fatty acids, choline, phosphocholine, glucose, glutamate,
glutamine, aspartate and phosphoethanolamine. Spectral
signal integration was performed over the signals of these
metabolites and the significance of the relative integral
values with respect to the final diagnosis was assessed.
Metabolites with a significantly different signal between
cirrhotic and non-cirrhotic tissue according to the Mann-
Whitney U test are reported in Table II and presented in
Figs. 4 and 5.
Metabolic profiles. In liver tissue, there is an abundance of
large macromolecules, lipids and fatty acids. However, in our
study, the liver content in these metabolites shows no clear
correlation to the degree of the disease. Variability in the
total relative fat content of the different samples, calculated
as the added area of the individual fatty acid peaks, seem to
have no correlation, at least in the HR-MAS spectra, to the
liver disease stage. There were statistically significant
differences between cirrhotic and non-cirrhotic liver tissue in
the levels of phospholipid intermediates (Table II and Fig. 4).
In the case of cirrhotic tissue, the amount of free choline was
found to be lower, whereas the amounts of phosphocholine
and phosphoethanolamine were found to be higher than the
respective amounts in non-cirrhotic tissue. There were also
significant variations between cirrhotic and non-cirrhotic
samples in some amino acids. In cirrhosis, the levels of
glutamate were increased whereas those of glutamine and
aspartate were decreased. Further analysis of the levels of
glutamate and glutamine also showed some correlation with
the disease stage (Glutamate, Pearson correlation coefficient
0.39, p=0.04; Glutamine, Pearson correlation coefficient -0.51,
p=0.03). The mean values for these metabolites in the
different disease stages are presented in Fig. 5. Other
identified metabolites with statistically significant differences
between cirrhotic and non cirrhotic samples include glucose
and some unsaturated fatty acids (UFA, signal at 2.70 ppm).
Glucose also showed some correlation (Pearson correlation
coefficient -0.42, p=0.04) with the liver disease stage.
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Figure 3. (A). Scores of the LV1 and the LV2 of the PLS-DA model (R2=30.2%, Q2=78.2%) for the discrimination between cirrhotic (white circles) and non-
cirrhotic (black triangles) chronic liver disease biopsies based on the 1H HR-MAS 1D presaturation single-pulse experiment. (B). Loadings plot for the PLS-DA
model for discrimination between cirrhotic and non cirrhotic chronic liver disease biopsies with labels on the resonances of the most significant metabolites.
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Discussion
Metabolic profiles of chronic liver disease biopsies provided
differential patterns between cirrhosis and non-cirrhosis and
allow the determination of progressive metabolic alterations
associated to chronic hepatic disease. Previous studies of
similar characteristics focused their analysis and conclusions
in the study of lipid composition (21). In this work, we report
that metabolic alterations associated to liver disease stage
affect essential metabolic processes beyond lipid metabolism.
Early stages of chronic liver disease seem to have important
metabolic consequences.
Choline-containing compounds are important molecules
in the synthesis and degradation of phospholipids, which are
an essential component of the different membranes. We
observed some changes in the levels of these molecules in
liver cirrhosis. Similar alterations in the levels of phospholipid
precursors have been reported both ‘in vitro’ and ‘in vivo’ in
previous studies (42,43). The interpretation of variations in
these signals is not trivial. Altered intensity of these signals
may not only suggest altered synthesis or degradation of
membranes, but it may also indicate changes in the synthesis
and the degradation combined or just in the mobility of the
choline-containing compound parts. In the case of liver
fibrosis, which is characterized by the replacement of liver
tissue by fibrous scar tissue, the decrease in choline may
reflect a decrease in membrane metabolism and possibly in
liver functional tissue and hepatocytes. Phosphoethanolamine,
which is also an intermediate in the metabolism of phospho-
lipids, is increased in cirrhotic tissue. However, its detailed
physiological significance is largely unknown. Differently
to choline-containing compounds, phosphoethanolamine
does not appear as a common intermediate in membrane
degradation. Increased phosphoethanolamine levels suggest
that phosphatidylethanolamine metabolism has been
activated or that incorporation of phosphatidylethanolamine
in the membranes has been partially impaired. In the case of
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Table II. The most statistically significant resonance intensity
relative values between non-cirrhotic and cirrhotic samples
with the standard deviation and the p-values derived from the
Mann-Whitney U test.
–––––––––––––––––––––––––––––––––––––––––––––––––
Metabolite signal/classification Mean ± SD p-value
–––––––––––––––––––––––––––––––––––––––––––––––––
Unsaturated fatty acyl chains (UFA)
-CH=CH-CH2- (2.77 ppm) 0.062
Chronic hepatitis 141±90
Cirrhosis 409±342
Choline (3.20 ppm) 0.057
Chronic hepatitis 134±43
Cirrhosis 85±60
Phosphocholine (3.22 ppm) 0.041
Chronic hepatitis 148±67
Cirrhosis 220±138
TMAO (3.26 ppm) 0.062
Chronic hepatitis 244±02
Cirrhosis 110±81
·-glucose (3.41 ppm) 0.036
Chronic hepatitis 91±31
Cirrhosis 59±32
Glutamate (3.62 ppm) 0.031
Chronic hepatitis 59±49
Cirrhosis 100±67
Glutamine (3.78 ppm) 0.065
Chronic hepatitis 101±84
Cirrhosis 27±69
Aspartate (3.86 ppm) 0.049
Chronic hepatitis 83±27
Cirrhosis 51±82
ß-glucose (3.89 ppm) 0.067
Chronic hepatitis 119±133
Cirrhosis 60±23
Phosphoethanolamine (4.01 ppm) 0.044
Chronic hepatitis 290±131
Cirrhosis 497±302
–––––––––––––––––––––––––––––––––––––––––––––––––
Figure 4. Scheme showing bar graphs for the metabolites involved in
phospholipid metabolism at the different liver disease stages (1, black; 2,
dark gray; 3, light gray; 4/cirrhosis, white).
Figure 5. Scheme showing bar graphs for the metabolites involved in the
ammonia detoxification by the liver at the different liver disease stages (1,
black; 2, dark gray; 3, light gray; 4/cirrhosis, white).
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liver disease, the second pathway seems more probable.
The methylation of phosphatidylethanolamine, which is
stimulated by methionine, is responsible for 30% of the
phosphatidylcholine synthesis in the liver (44). Methionine
metabolism is typically altered in advanced liver disease
(45), being a probable reason responsible for the abnormal
levels of phosphoethanolamine observed in this work.
Nevertheless, the metabolic alterations generally observed in
advanced liver disease are so complex that many different
pathways are probably affected. In fact, levels of TMAO are
also decreased, in agreement with previous studies (46),
suggesting also a possible impairment of the N-oxidation
pathway of choline and glycerophosphorylcholine (47).
Amino acid metabolism, a major hepatic metabolic
process, is shifted towards the production and accumulation
of glutamate. Most amino acids were easily observable in the
spectra of samples with lower relative fat content. Some of
them presented interesting differences between cirrhotic and
non cirrhotic tissue. Previous HR-MAS studies on human
liver biopsies reported decreased alanine in cirrhotic tissue
(28). In the spectra presented here, alanine was not visible in
all the cases. When alanine was visible, a trend towards
decreased levels in cirrhotic tissue was observed although no
statistically significant differences were detected. Other
amino acids with variations present in human liver diseased
tissue include aspartate, glutamine and glutamate. Some of
the signals belonging to these molecules are located in
regions with no lipid or fatty acid overlapping and, therefore,
were easily identified. However, strong differences in the
signal-to-noise ratios for these signals due to the variability
in samples size and fat content made the quantification quite
challenging. Interestingly, glutamine levels in cirrhotic tissue
were always lower than those in non cirrhotic tissue samples.
The levels of glutamate and glutamine in stages 2 and 3 were
very similar (Fig. 5). Glutamine is metabolically linked to the
ammonium detoxification in the body by the hepatocytes.
Decreased levels of glutamine may reflect increased hepatic
dysfunction and/or destruction of hepatocytes. Interestingly,
glutamate, which is the precursor of glutamine in the
glutamine-synthase reaction, is increased in cirrhotic liver,
supporting this conclusion. The lower levels of aspartate and
glutamine together with the higher level of glutamate may
indicate a shift towards glutamate production, a net release of
ammonium and impaired ammonium detoxification ability.
Diseased liver is subject to oxidative stress (14). In this
context, it is very possible to have a metabolic shift towards
the synthesis of precursors of glutathione, a well known cell
antioxidant. All these facts are consistent with the hypothesis
that increased circulating ammonium is the major culprit for
the origin of hepatic encephalopathy (48), a serious
complication of advanced liver disease.
The observed decrease in the glucose signal intensity
suggests alterations in the glycolysis and in the glucose
production in the liver, as has been reported in acute liver
injury (46,47). Interestingly, these alterations seem to appear
from the early stages of the liver disease (Fig. 4). The
transition to cirrhotic liver seems to produce a less dramatic
change in the levels of glucose. On the other hand, an increase
in the levels of UFAs with the disease stage was detected,
albeit with low statistical significance, suggesting that lipid
metabolism, an important part of the liver metabolism, is also
compromised with the fibrotic stage.
In summary, the metabolic characterization of liver tissue
from needle biopsies by HR-MAS NMR spectroscopy
provided detailed patterns for cirrhotic and non-cirrhotic
chronic liver disease tissue. The metabolic composition of
the liver tissue was highly consistent with previous studies.
Clear metabolic differences between cirrhosis and non-
cirrhotic tissue exist. The most relevant of these differences
are the glutamate increase and the glutamine and glucose
decreases. Other differences include aspartate, choline,
phosphocholine and phosphoethanolamine. Correlations
with respect to the liver disease stage of some of these
metabolites, namely, glutamate, glutamine and glucose,
suggest that hepatic function is progressively impaired with
the development of hepatic fibrosis. Overall, this work
suggests that the additional information obtained by NMR
metabolomics applied to needle biopsies of human liver
may be useful for assessing metabolic alterations and liver
dysfunction in chronic liver disease.
Acknowledgements
This study was partly financed by grants from the Ministerio
de Educación y Ciencia del Gobierno de España (SAF2007-
6547 and SAF2008-00270) and the Consellería de Sanidad
de la Generalitat Valenciana (GVASAN/AP014/2009). D.M.
gratefully acknowledges the Ministerio de Educación y
Ciencia del Gobierno de España for a Ramon y Cajal 2006
Contract.
References
1. Guyton AC and Hall JE (eds.): Medical Physiology. Elsevier
Saunders, Philadelphia, PA, 2006.
2. Ros PR and Mortele KJ: Diffuse liver disease. Clin Liver Dis 6:
181-201, 2002.
3. Simpson KJ and Finlayson ND: Clinical evaluation of liver
disease. Baillieres Clin Gastroenterol 9: 639-659, 1995.
4. Friedman LS and Keeffe B (eds.): Handbook of liver disease.
Churchill Livingstone, London, 2004.
5. Hunt N and Fleming K: Reproducibility of liver biopsy grading
and staging. Liver 19: 169-170, 1999.
6. Brunt EM: Grading and staging the histopathological lesions of
chronic hepatitis: the Knodell histology activity index and
beyond. Hepatology 31: 241-246, 2000.
7. Ishak K, Baptista A, Bianchi L, et al: Histological grading and
staging of chronic hepatitis. J Hepatol 22: 696-699, 1995.
8. Friedman SL: Liver fibrosis - from bench to bedside. J Hepatol
38 (Suppl 1): S38-S53, 2003.
9. Pinzani M, Rombouts K and Colagrande S: Fibrosis in chronic
liver diseases: diagnosis and management. J Hepatol 42: S22-S36,
2005.
10. Dezortova M, Taimr P, Skoch A, Spicak J and Hajek M:
Etiology and functional status of liver cirrhosis by 31P MR
spectroscopy. World J Gastroenterol 11: 6926-6931, 2005.
11. Kuriyama S, Yokoyama F, Inoue H, et al: Sequential assessment
of the intrahepatic expression of epidermal growth factor and
transforming growth factor-beta1 in hepatofibrogenesis of a rat
cirrhosis model. Int J Mol Med 19: 317-324, 2007.
12. Canbay A, Friedman S and Gores GJ: Apoptosis: the nexus of
liver injury and fibrosis. Hepatology 39: 273-278, 2004.
13. Ramadori G and Saile B: Inflammation, damage repair, immune
cells, and liver fibrosis: specific or nonspecific, this is the question.
Gastroenterology 127: 997-1000, 2004.
14. Poli G: Pathogenesis of liver fibrosis: role of oxidative stress.
Mol Aspects Med 21: 49-98, 2000.
15. Gutierrez-Reyes G, Gutierrez-Ruiz MC and Kershenobich D:
Liver fibrosis and chronic viral hepatitis. Arch Med Res 38:
644-651, 2007.
MARTÍNEZ-GRANADOS et al:  METABOLIC PROFILING OF HUMAN CHRONIC LIVER DISEASE116
111-117.qxd  18/11/2010  09:19 Ì  ™ÂÏ›‰·116
16. Kaji K, Yoshiji H, Kitade M, et al: Impact of insulin resistance
on the progression of chronic liver diseases. Int J Mol Med 22:
801-808, 2008.
17. Naveau S, Raynard B, Ratziu V, et al: Biomarkers for the
prediction of liver fibrosis in patients with chronic alcoholic
liver disease. Clin Gastroenterol Hepatol 3: 167-174, 2005.
18. Ratziu V, Giral P, Munteanu M, et al: Screening for liver
disease using non-invasive biomarkers (FibroTest, SteatoTest
and NashTest) in patients with hyperlipidaemia. Aliment
Pharmacol Ther 25: 207-218, 2007.
19. Salcedo X, Medina J, Sanz-Cameno P, Garcia-Buey L, Martin-
Vilchez S and Moreno-Otero R: Review article: angiogenesis
soluble factors as liver disease markers. Aliment Pharmacol
Ther 22: 23-30, 2005.
20. Parola M, Robino G and Dianzani MU: 4-hydroxy-2,3-alkenals
as molecular mediators of oxidative stress in the pathogenesis of
liver fibrosis (review). Int J Mol Med 4: 425-432, 1999.
21. Cobbold JF, Patel JH, Goldin RD, et al: Hepatic lipid profiling
in chronic hepatitis C: An in vitro and in vivo proton magnetic
resonance spectroscopy study. J Hepatol 52: 16-24, 2010.
22. Fischbach F and Bruhn H: Assessment of in vivo 1H magnetic
resonance spectroscopy in the liver: a review. Liver Int 28:
297-307, 2008.
23. Sijens PE, Edens MA, Bakker SJ and Stolk RP: MRI-determined
fat content of human liver, pancreas and kidney. World J
Gastroenterol 16: 1993-1998, 2010.
24. Springer F, Machann J, Claussen CD, Schick F and Schwenzer NF:
Liver fat content determined by magnetic resonance imaging
and spectroscopy. World J Gastroenterol 16: 1560-1566, 2010.
25. Cheng LL, Ma MJ, Becerra L, et al: Quantitative neuropathology
by high resolution magic angle spinning proton magnetic
resonance spectroscopy. Proc Natl Acad Sci USA 94: 6408-6413,
1997.
26. Sitter B, Bathen TF, Singstad TE, et al: Quantification of
metabolites in breast cancer patients with different clinical
prognosis using HR MAS MR spectroscopy. NMR Biomed:
January 25, 2010 (Epub ahead of print).
27. Martinez-Bisbal MC, Monleon D, Assemat O, et al:
Determination of metabolite concentrations in human brain
tumour biopsy samples using HR-MAS and ERETIC
measurements. NMR Biomed 22: 199-206, 2009.
28. Martinez-Granados B, Monleon D, Martinez-Bisbal MC, et al:
Metabolite identification in human liver needle biopsies by
high-resolution magic angle spinning 1H NMR spectroscopy.
NMR Biomed 19: 90-100, 2006.
29. Monleon D, Morales JM, Gonzalez-Darder J, et al: Benign and
atypical meningioma metabolic signatures by high-resolution
magic-angle spinning molecular profiling. J Proteome Res 7:
2882-2888, 2008.
30. Griffin JL, Bollard M, Nicholson JK and Bhakoo K: Spectral
profiles of cultured neuronal and glial cells derived from
HRMAS (1)H NMR spectroscopy. NMR Biomed 15: 375-384,
2002.
31. Hong YS, Coen M, Rhode CM, et al: Chemical shift calibration
of 1H MAS NMR liver tissue spectra exemplified using a study
of glycine protection of galactosamine toxicity. Magn Reson
Chem 47 (Suppl 1): S47-S53, 2009.
32. Swanson MG, Zektzer AS, Tabatabai ZL, et al: Quantitative
analysis of prostate metabolites using 1H HR-MAS spectro-
scopy. Magn Reson Med 55: 1257-1264, 2006.
33. Weybright P, Millis K, Campbell N, Cory DG and Singer S:
Gradient, high-resolution, magic angle spinning 1H nuclear
magnetic resonance spectroscopy of intact cells. Magn Reson
Med 39: 337-345, 1998.
34. Cheng LL, Chang IW, Louis DN and Gonzalez RG: Correlation
of high-resolution magic angle spinning proton magnetic
resonance spectroscopy with histopathology of intact human
brain tumor specimens. Cancer Res 58: 1825-1832, 1998.
35. Maxwell RJ, Martinez-Perez I, Cerdan S, et al: Pattern
recognition analysis of 1H NMR spectra from perchloric acid
extracts of human brain tumor biopsies. Magn Reson Med 39:
869-877, 1998.
36. Duarte IF, Stanley EG, Holmes E, et al: Metabolic assessment
of human liver transplants from biopsy samples at the donor and
recipient stages using high-resolution magic angle spinning 1H
NMR spectroscopy. Anal Chem 77: 5570-5578, 2005.
37. Cox IJ, Sharif A, Cobbold JF, Thomas HC and Taylor-
Robinson SD: Current and future applications of in vitro
magnetic resonance spectroscopy in hepatobiliary disease.
World J Gastroenterol 12: 4773-4783, 2006.
38. Martinez-Bisbal MC, Marti-Bonmati L, Piquer J, et al: 1H and
13C HR-MAS spectroscopy of intact biopsy samples ex vivo
and in vivo 1H MRS study of human high grade gliomas. NMR
Biomed 17: 191-205, 2004.
39. Ludwig J, Batts KP, Moyer TP and Poterucha JJ: Advances in
liver biopsy diagnosis. Mayo Clin Proc 69: 677-678, 1994.
40. Waters NJ, Garrod S, Farrant RD, et al.: High-resolution magic
angle spinning (1)H NMR spectroscopy of intact liver and
kidney: optimization of sample preparation procedures and
biochemical stability of tissue during spectral acquisition. Anal
Biochem 282: 16-23, 2000.
41. Piotto M, Elbayed K, Wieruszeski JM and Lippens G: Practical
aspects of shimming a high resolution magic angle spinning
probe. J Magn Reson 173: 84-89, 2005.
42. Schlemmer HP, Sawatzki T, Sammet S, et al: Hepatic
phospholipids in alcoholic liver disease assessed by proton-
decoupled 31P magnetic resonance spectroscopy. J Hepatol 42:
752-759, 2005.
43. Tarachiwin L, Ute K, Kobayashi A and Fukusaki E: 1H NMR
based metabolic profiling in the evaluation of Japanese green
tea quality. J Agric Food Chem 55: 9330-9336, 2007.
44. Sundler R and Akesson B: Regulation of phospholipid
biosynthesis in isolated rat hepatocytes. Effect of different
substrates. J Biol Chem 250: 3359-3367, 1975.
45. Mato JM and Ortiz P: Metabolism of methionine in liver
disease. Methods Find Exp Clin Pharmacol 18 (Suppl B): 35-46,
1996.
46. Constantinou MA, Tsantili-Kakoulidou A, Andreadou I,
Iliodromitis EK, Kremastinos DT and Mikros E: Application of
NMR-based metabonomics in the investigation of myocardial
ischemia-reperfusion, ischemic preconditioning and antioxidant
intervention in rabbits. Eur J Pharm Sci 30: 303-314, 2007.
47. Waters NJ, Waterfield CJ, Farrant RD, Holmes E and
Nicholson JK: Metabonomic deconvolution of embedded
toxicity: application to thioacetamide hepato- and nephrotoxicity.
Chem Res Toxicol 18: 639-654, 2005.
48. Rodrigo R, Cauli O, Gomez-Pinedo U, et al: Hyperammonemia
Induces Neuroinflammation that Contributes to Cognitive
Impairment in Rats with Hepatic Encephalopathy. Gastro-
enterology 139: 675-684, 2010.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  27:  111-117,  2011 117
111-117.qxd  18/11/2010  09:19 Ì  ™ÂÏ›‰·117
